Browse > Article
http://dx.doi.org/10.3839/jabc.2022.008

Artesunate inhibits collagen-induced human platelets aggregation through regulation of PI3K/Akt and MAPK pathway  

Lee, Dong-Ha (Department of Biomedical Laboratory Science, Molecular Diagnostics Research Institute, Namseoul University)
Publication Information
Journal of Applied Biological Chemistry / v.65, no.1, 2022 , pp. 57-62 More about this Journal
Abstract
Excessive activation and aggregation of platelets is a major cause of cardiovascular disease. Therefore, inhibition of platelet activation and aggregation is considered an attractive therapeutic target in preventing and treating cardiovascular diseases. In particular, strong platelet activation and aggregation by collagen secreted from the vascular endothelium are characteristic of vascular diseases. Artesunate is a compound extracted from the plant roots of Artemisia or Scopolia species, and has been reported to be effective in anticancer and Alzheimer's disease fields. However, the effect and mechanism of artesunate on collagen-induced platelet activation and aggregation have not been elucidated. In this study, the effect of artesunate on collagen-induced human platelet aggregation was confirmed and the mechanism of action of artesunate was clarified. Artesunate inhibited the phosphorylation of PI3K/Akt and Mitogen-activated protein kinases, which are phosphoproteins that are known to act in the signal transduction process when platelets are activated. In addition, artesunate decreased TXA2 production and decreased granule secretion in platelets such as ATP and serotonin release. As a result, artesunate strongly inhibited platelet aggregation induced by collagen, a strong aggregation inducer secreted from vascular endothelial cells, with an IC50 of 106.41 µM. These results suggest that artesunate has value as an effective antithrombotic agent for inhibiting the activation and aggregation of human platelets through vascular injury.
Keywords
Artesunate; Granule secretion; Mitogen-activated protein kinases; PI3K/Akt; Platelet aggregation; $TXA_2$;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Calderwood DA (2004) Integrin activation. J Cell Sci 117: 657-666   DOI
2 Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ (1996) p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271: 27723-27729. doi: 10.1074/jbc.271.44.27723   DOI
3 Schwartz SM, Heimark RL, Majesky MW (1990) Developmental mechanisms underlying pathology of arteries. Physiol Rev 70: 1177-1209. doi: 10.1152/physrev.1990.70.4.1177   DOI
4 Morello F, Perino A, Hirsch E (2009) Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 82: 261-271   DOI
5 Cattanco M, Tenconi PM, Lecchi A, Mannucci PM (1991) In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 62: 717-724. doi: 10.1016/0049-3848(91)90375-7   DOI
6 Su CY, Shiao MS, Wang CT (1999) Differential effects of ganodermic acid S on the thromboxane A2-signaling pathways in human platelets. Biochem Pharmacol 58: 587-595. doi: 10.1016/s0006-2952(99)00136-7   DOI
7 Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ (2010) Platelet JNK1 is involved in secretion and thrombus formation. Blood 115: 4083-4092. doi: 10.1182/blood-2009-07-233932   DOI
8 Kramer RM, Roberts EF, Strifler BA, Johnstone EM (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 270: 27395-27398. doi: 10.1074/jbc.270.46.27395   DOI
9 Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M (2002) Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 531: 475-482. doi: 10.1016/s0014-5793(02)03587-1   DOI
10 Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294. doi: 10.1056/NEJM199405053301808   DOI
11 Sabatine MS, Jang IK (2000) The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 109: 224-237   DOI
12 Patrono C (2001) Aspirin: new cardiovascular uses for an old drug. Am J Med 110: 62S-65S. doi: 10.1016/s0002-9343(00)00645-8   DOI
13 Jackson SP (2011) Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 17: 1423-1436. doi: 10.1038/nm.2515   DOI
14 Wonerow P, Obergfell A, Wilde JI, Bobe R, Asazuma N, Brdicka T, Leo A, Schraven B, Horejsi V, Shattil SJ, Watson SP (2002) Differential role of glycolipid-enriched membrane domains in glycoprotein VI- and integrin-mediated phospholipase Cgamma2 regulation in platelets. Biochemical Journal 364: 755-765. doi: 10.1042/bj20020128   DOI
15 Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H (2000) The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 60: 1069-1074. doi: 10.1016/S0006-2952(00)00417-2   DOI
16 Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103: 4A-10A   DOI
17 Chuang WY, Kung PH, Kuo CY, Wu CC (2013) Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb Haemost 109: 1120-1130. doi: 10.1160/TH12-09-0636   DOI
18 Lu H, Wang B, Cui N, Zhang Y (2018) Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS-dependent p38 MAPK and protects against cerebral ischemia-reperfusion injury. Mol Med Rep 17: 6639-6646. doi: 10.3892/mmr.2018.8666   DOI
19 Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96: 1109-1116   DOI
20 Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M (1999) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94: 3800-3805   DOI
21 Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893-901. doi: 10.1182/blood-2008-05-155978   DOI
22 Thanaketpaisarn O, Waiwut P, Sakurai H, Saiki I (2011) Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int J Oncol 39: 279-285. doi: 10.3892/ijo.2011.1017   DOI
23 Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, Lin CC, Lin BR, Jeng JH (2011) Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 219: 559-565. doi: 10.1016/j.atherosclerosis.2011.09.031   DOI
24 McNicol A, Shibou TS (1998) Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb Res 92: 19-26. doi: 10.1016/s0049-3848(98)00097-8   DOI
25 Shin JH, Kwon HW, Lee DH (2019) Ginsenoside F4 inhibits platelet aggregation and thrombus formation by dephosphorylation of IP3RI and VASP. J Appl Biol Chem 62: 93-100   DOI